VICTORION-1 PREVENT (V-1P) is an ongoing randomized clinical trial evaluating the efficacy and safety of inclisiran, a siRNA lipid lowering therapy targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression, in patients with high cardiovascular (CV) risk but without established atherosclerotic CV disease (ASCVD) [1]. This evidence concerns the gene PCSK9 and atherosclerosis.